Loading
Joohyuk Sohn is a Yonsei breast oncologist and investigator on the DESTINY-Breast and TROPION trials.
Joohyuk Sohn is Professor of Medical Oncology at Severance Hospital, Yonsei University, in Seoul, specialising in breast cancer. He leads breast medical oncology trials at Yonsei Cancer Center and has been an investigator on the DESTINY-Breast trials of trastuzumab deruxtecan and the TROPION trials of datopotamab deruxtecan, bringing Korean cohorts into HER2-low, TROP2 antibody-drug conjugate and CDK4/6 studies. His publications include work on cMET activation and resistance to EGFR-directed therapy in triple-negative breast cancer, the D-CARE trial of adjuvant denosumab in early breast cancer, and a phase 3 trial of polymeric micelle-formulated paclitaxel in HER2-negative breast cancer. His interests are HER2-low disease and antibody-drug conjugates.
Patients with hormone-receptor-positive metastatic breast cancer that has stopped responding to endocrine therapy can be offered trastuzumab deruxtecan as their first chemotherapy-type treatment if the tumour shows any HER2 staining, rather than waiting until after conventional chemotherapy. Whether to use it before or after chemotherapy is now a choice, since overall survival was not shown to differ and the drug carries a risk of lung inflammation.
Patients whose breast cancer was previously called HER2-negative may now be eligible for an effective HER2-directed drug if their tumour has even low-level HER2 staining, so pathology reports must now distinguish HER2-low (1+ or 2+/ISH-negative) from HER2-zero. This applies to metastatic disease after at least one line of chemotherapy; it does not mean these patients benefit from trastuzumab or other older HER2 drugs.
Women with hormone-receptor-positive, HER2-negative breast cancer that has spread to lymph nodes and has other high-risk features can now be offered two years of abemaciclib alongside their hormone therapy, with a durable reduction in relapse. It does not apply to node-negative or low-risk disease, and the diarrhoea and cost are real trade-offs to discuss.
Shares DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group, Trastuzumab deruxtecan, HER2, HER2-positive breast cancer.
Shares DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer, Trastuzumab deruxtecan, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
Shares DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group, Trastuzumab deruxtecan, HER2, HER2-positive breast cancer.
Shares monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer, TROP2, Datopotamab deruxtecan, Trastuzumab deruxtecan.
Shares DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group, TROP2, HER2, HER2-positive breast cancer.
Shares DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group, Trastuzumab deruxtecan, HER2, HER2-positive breast cancer.
Shares DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer, DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group, HR-positive / HER2-negative breast cancer.
Shares TROP2, Trastuzumab deruxtecan, HER2, HER2-positive breast cancer.